Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma: Results of pediatric oncology group (now children's oncology group) study 9486

Cancer

Volumn 103, Issue 4, 2005, Pages 850-857

  Rodriguez Galindo, Carlos ^a,b   Wofford, Marcia ^c   Castleberry, Robert P ^d   Swanson, Gregory P ^e   London, Wendy B ^f   Fontanesi, James ^g   Pappo, Alberto S ^h   Douglass, Edwin C ⁱ  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Deaconess Medical Center Spokane   (United States)

^f University of Florida   (United States)

^g UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

Chemotherapy; Nasopharyngeal carcinoma; Pediatric patients; Radiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; MANNITOL; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG INFUSION; ENDOCRINE DISEASE; EPSTEIN BARR VIRUS; FEMALE; HEARING LOSS; HUMAN; INFECTION; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; SCHOOL CHILD; STOMATITIS; SURVIVAL RATE; VIRUS INFECTION; XEROSTOMIA;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; EPSTEIN-BARR VIRUS INFECTIONS; FLUOROURACIL; HERPESVIRUS 4, HUMAN; HUMANS; LEUCOVORIN; METHOTREXATE; NASOPHARYNGEAL NEOPLASMS; SURVIVAL RATE;

EID: 13444303837     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20823     Document Type: Article

References (55)

1. Marks JE, Phillips JL, Menck HR. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer, 1998; 83:582-588.
2. Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003;4:13-21.
3. Greene MH, Fraumeni JF, Hoover R. Nasopharyngeal cancer among young people in the United States: racial variations by cell type. J Natl Cancer Inst, 1977;58:1267-1270.
4. Pao WJ, Hustu HO, Douglass EC, Beckford NS, Kun LE, Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int J Radiat Oncol Biol Phys. 1989;17:299-305.
5. Ayan I, Altun M, Nasopharyngeal carcinoma in children: retrospective review of 50 patients. Int J Radiat Oncol Biol Phys, 1996;35:485-492.
6. Ghim TT, Briones M, Mason P, et al. Effective adjuvant chemotherapy for advanced nasopharyngeal carcinoma in children: a final update of a long-term prospective study in a single institution. J Pediatr Hematol Oncol. 1998;20;131-135.
7. Lobo-Sanahuja F, Garcia I, Carranza A, Camacho A. Treatment and outcome of undifferentiated carcinoma of the nasopharynx in childhood: a 13-year experience. Med Pediatr Oncol. 1986:14:6-11.
8. Roper HP, Essex-Carter A, Marsden HB, Dixon PF, Campbell RHA. Nasopharyngeal carcinoma in children. Pediatr Hematol Oncol. 1986;3:143-152.
9. Gasparini M, Lombardi F, Rottoli L, Ballerini E, Morandi F. Combined radiotherapy and chemotherapy in stage T3 and T4 nasopharyngeal carcinoma in children. J Clin Oncol. 1988;6;491-494.
10. Arush MW, Stein ME, Bosenblatt E, et al. Advanced nasopharyngeal carcinoma in the young: the Northern Israel oncology center experience, 1973-1991. Pediatr Hematol Oncol. 1995;12:271-276.
11. Werner-Wasik M, Winkler P, Uri A, et al. Nasopharyngeal carcinoma in children. Med Pediatr Oncol. 1996:26:352-358.
12. Strojan P, Benedik MD, Kragelj R, et al. Combined radiation and chemotherapy for advanced undifferentiated nasopharyngeal carcinoma in children. Med Pediatr Oncol. 1997;28:366-369.
13. Ingersoll L, Woo SY, Donaldson S, et al. Nasopharyngeal carcinoma in the young: a combined M.D. Anderson and Stanford experience. Int J Radiat Oncol Biol Phys. 1990;19:881-887.
14. Berberoglu S, Ilhan I, Cetindag F, Sunter O, Nasopharyngeal carcinoma in Turkish children: review of 33 cases. Pediatr Hematol Oncol. 2001;18:309-315.
15. Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23:261-270.
16. Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys, 1992;23:271-280.
17. Sanguineti G, Geara FB, Garden AS, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997;37:985-996.
18. Decker DA, Drelichman A, Al-Sarraf M, Chemotherapy for nasopharyngeal carcinoma; a ten-year experience. Cancer. 1983;52:602-605.
19. Al-Sarraf M, Chemotherapeutic management of head and neck cancer. Cancer Metast Rev. 1987;6:191-198.
20. Chan ATC, Teo PML, Leung TWT, Johnson PJ. The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer. 1998;82:1003-1012.
21. Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 1994;5:87-89.
22. Chi KH, Chan WK, Cooper DL, Yen SH, Lin CZ, Chen KY. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil and leucovorin in nasopharyngeal carcinoma. Cancer. 1994;73:247-252.
23. Gebbia V, Zerillo G, Restivo G, et al. Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma. A retrospective analysis of 40 cases. Br J Cancer. 1993;68:191-194.
24. Huang SC, Lui LT, Lynn TS. Nasopharyngeal cancer study III. A review of 1206 patients treated with combined modalities. Int J Radiat Oncol Biol Phys. 1985:11:1789-1793.
25. Douglass EC, Fontanesi J, Ribeiro RC, Hawkins E. Improved longterm disease-free survival in nasopharyngeal carcinoma (NPC) in childhood and adolescence: a multi-institution treatment protocol [abstract]. Proc Am Soc Clin Oncol. 1996;15:A1470.
26. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: J.B.Lippincott, 1992:33-38.
27. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958:53:457-481.
28. Peto P, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II, analysis and examples. Br J Cancer. 1977;35:1-39.
29. Mertens R, Granzen B, Lassay L, Gademann G, Hess CF, Heimann G. Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Cancer. 1997:80:951-959.
30. Tsukuda M, Sawaki S, Yanoma S. Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 1993;120:115-118.
31. Treuner J, Niethammer D, Dannecker G, Hagmann R, Neef V, Hofschneider PH. Successful treatment of nasopharyngeal carcinoma with Interferon. Lancet. 1980;12:817-818.
32. Chan ATC, Teo PML, Leung TWT, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995;33:569-577.
33. International Nasopharynx Cancer Study Group: VUMCA I Trial. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥ N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996:35:463-469.
34. Ma J, Mai H-Q, Hong M-H, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1350-1357.
35. Chua DTT, Sham JST, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 1998;83:2270-2283.
36. Hong S, Wu H-G, Chie EK, et al. Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1999:45:901-905.
37. Dewit L. Combined treatment of radium and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 1987;13:403-426.
38. Wolden SL, Zelefsky MJ, Kraus DH, et al. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1105-1110.
39. Cheng SH, Jian JJ-M, Tsai SYC, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys, 2000;48:1323-1330.
40. Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol. 2002;20:1845-1852.
41. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.
42. Chan ATC, Teo PML, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20:2038-2044.
43. Danenberg PV, Danenberg KD. Effect of 5,10-methylenetetrahydrofolate and the dissociation of 5-fluorodeoxyuridylate binding of human thymidylate synthetase: evidence for an ordered mechanism. Biochemistry. 1978;17:4018-4024.
44. Evans RM, Laskin JD, Hakala MT. Assessment of growthlimiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res. 1980;40:4113-4122.
45. Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther. 1990;47:1-19.
46. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992:10:896-903.
47. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345.
48. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12-22.
49. Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target definition. Semin Oncol. 2002;29(Suppl. 19):63-70.
50. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333-3355.
51. Lo YMD, Chay LYS, Lo K-W, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59:1188-1191.
52. Lo YMD, Leung S-F, Chan LYS, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 2000;60:2351-2355.
53. Lo YMD, Chan LYS, Chan ATC, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999;59:5452-5455.
54. Lo YMD, Chan ATC, Chan LYS, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000; 60:6878-6881.
55. Lin J-C, Wang W-Y, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461-2470.